ArticleHemaSphere2026
Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma.
Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in terms of bispecific antibodies (BsAbs) targeting single tumor-associated antigens in multiple myeloma (MM), not all patients respond, and most eventually relapse. Using flow cytometry, we found that BCMA and GPRC5D expression is highly heterogeneous within and between patients. Dual targeting with ramantamig (JNJ-79635322), a trispecific antibody targeting both BCMA and GPRC5D on the tumor cell surface, has been hypothesized to improve efficacy by overcoming heterogeneous target expression and preventing resistance due to antigen escape. Using T-cells from healthy donors, ramantamig was significantly more effective than mono-targeting antibodies against BCMA
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.